Faculty

Institution

Unit

Venue

Adam Kittai

Oregon Health & Science University

Affiliations

OHSU School of Medicine

Department Of Medicine

Department of Medicine

Division of Hematology & Medical Oncology

Department Of Medicine

Hematology and Medical Oncology

Oregon Health & Science University

Adam Kittai is a Senior Professor at Oregon Health & Science University specializing in hematology and oncology. His research focuses on hematological malignancies, particularly leukemia, lymphoid neoplasia, and Richter transformation, alongside cancer immunotherapy and pharmacology. His recent work includes international consensus recommendations for Richter transformation diagnosis, phase 3 trials of novel combinations for relapsed follicular lymphoma, and studies on CAR-T therapy outcomes, including cytokine release syndrome and comorbidity indices. He has also investigated BTK inhibitor cost-effectiveness in Medicare patients with chronic lymphocytic leukemia.

Honors

Create free account to unlock more features

Experiences

Create free account to unlock more features

Education

Create free account to unlock more features

Adam Kittai

Oregon Health & Science University

You can click a keyword to filter the displayed items

hematology oncology medicine immunology hematological malignancies leukemia lymphoid neoplasia pharmacology cancer research cancer immunotherapy pharmacotherapy cellular therapy cancer treatment medicinal research cancer care chronic lymphocytic leukemia immunotherapy clinical immunology dermatology clinical transplantation survival analysis cell therapy therapeutic targets cell transplantation malignant blood disorders hemostasis oncogenes car t-cell therapy richter transformation enzyme inhibition bone marrow transplantation cancer management regenerative medicine surgical oncology jama oncology immune checkpoint inhibitors transplantation medicine clinical evidence experimental medicine laboratory medicine thrombosis comorbidity clinical mycology anti-cancer agents non-hodgkin lymphoma cell death cohort studies apoptosis immunohaematology cancer biology cancer disparities therapeutic efficacy novel therapies large b-cell lymphoma matching-adjusted indirect comparison syk inhibitor entospletinib adaptive immune system treatment options cord blood transplant surgery cellular immune responses anticoagulants inferior survival b-cell malignancies graft survival societal influence cytokines oncologic imaging blood cells immunomodulatory effects socioeconomic disparities cytokine release syndrome organ transplant patients btk inhibitors inferior outcomes allogeneic transplant

Notable Scholarly Works

Notable Federal Grants

Collaborators

208 | Comparative Efficacy of Ibrutinib Versus Other Covalent Bruton Tyrosine Kinase Inhibitors in First‐Line Chronic Lymphocytic Leukemia: A Matched‐Adjusted Indirect Comparison. Hematological Oncology (2025)

pharmacologymedicineoncologyhematological malignanciesleukemiapharmacotherapyanti-cancer agentsimmunotherapyimmunologymatched‐adjusted indirect comparisonhematology

3: Comparing and Contrasting Karyotype Scoring Guidelines for Evaluating Complex Karyotype in Chronic Lymphocytic Leukemia. Genetics in Medicine Open (2025)

pathologyhuman geneticschronic lymphocytic leukemiamedicinemolecular diagnosticscancer researchhematological malignanciescomplex karyotypeleukemiaadult t-cell leukemia-lymphomahematology

557 | Evaluating Uptake of Targeted Agents by Race/Ethnicity in Patients Receiving First‐Line Treatment for Chronic Lymphocytic Leukemia. Hematological Oncology (2025)

medicinelymphoid neoplasiaoncologyhematological malignanciesleukemiapharmacotherapyimmunologyhematologycancer care

A Phase II Multi-Institutional Study Evaluating the Safety and Efficacy of the Combination of Lisocabtagene Maraleucel and Zanubrutinib in Patients With Richter Transformation. Blood (2025)

clinical trialsoutcomes researchapplied pharmacologymedicinelisocabtagene maraleucelpatient safetypharmacotherapydrug safetyrichter transformationclinical researchsurgery

Comparative Efficacy of Ibrutinib Versus Other Covalent Bruton Tyrosine Kinase Inhibitors (Cbtkis) in First-Line (1L) Chronic Lymphocytic Leukemia (Cll): A Matched-Adjusted Indirect Comparison (Maic).. Journal of Clinical Oncology (2025)

pharmacologymalignant blood disorderschronic lymphocytic leukemiamedicineoncogenesmatched-adjusted indirect comparisononcologyhematological malignanciesleukemiapharmacotherapycomparative efficacyhematologytherapeutic targets

Consolidation (Cons) and Maintenance (Maint) Approaches in Primary Central Nervous System Lymphoma (Pcnsl) After High-Dose Methotrexate Induction in Transplant-Ineligible Patients. Blood (2025)

transplant-ineligible patientsmedicineclinical transplantationlymphoid neoplasiaorgan transplantationoncologytransplantation medicinecell transplantationradiation oncologyhigh-dose methotrexate inductionhematology

Cost Impact of Bruton’s Tyrosine Kinase Inhibitor Selection in Medicare Patients With Chronic Lymphocytic Leukemia. Journal of Comparative Effectiveness Research (2025)

pharmacoeconomicshealth policymedicinecost impactmedicare patientsoncologyhematological malignanciesleukemiapharmacotherapytreatment plan evaluationhealth economicshematologycancer carebruton ’

Cytokine Release Syndrome and Neurotoxicity Following Cd19 Car-T in B-Cell Lymphoma. Transplantation and Cellular Therapy (2025)

Roni ShouvalChristopher StrouseSoyoung KimTemitope OloyedeSairah AhmedFarrukh T AwanDanny LuanVeronika BachanovaTalha BadarMerav BarPere BarbaAmer M BeitinjanehAmanda CashenBhagirathbhai DholariaMahmoud ElsawySiddhartha GangulyPraveen Ramakrishnan GeethakumariUri GreenbaumHamza HashmiLaQuisa C HillMichael D JainTania JainPartow KebriaeiAdam S KittaiFrederick L LockePremal D LullaElena MeadJoseph P McGuirkAlberto MussettiTaiga NishihoriAmanda L OlsonMartina PennisiMiguel-Angel PeralesPeter A RiedellWael SaberAbu-Sayeef MirzaMargarida Magalhaes-SilvermanElizabeth J ShpallMohamed SorrorKitsada WudhikarnCameron J TurtleAmy MoskopMarcelo C Pasquini

cytokinesimmunity (medicine)b-cell lymphomacellular therapyimmunologycytokine release syndrome

Effect of Racial Disparities on Cancer Survival in Hematologic Malignancies: A Population-Based Analysis of Seer Data (2009–2019). Preventive Oncology & Epidemiology (2025)

Alma HabibYing HuangElectra D. PaskettSrinivas DevarakondaJames L. FisherAdam S. Kittai

disease progressionhealth care disparitieshematologic malignanciesracial disparitiesoncologyepidemiology of cancerhealth disparitiespublic healthpopulation-based analysiscancer survivalseer dataafrican american studiesracial discriminationepidemiology

Epcoritamab, Lenalidomide, and Rituximab Versus Lenalidomide and Rituximab for Relapsed or Refractory Follicular Lymphoma (Epcore Fl-1): A Global, Open-Label, Randomised, Phase 3 Trial. The Lancet (2025)

cancer immunotherapypathologylymphoid neoplasiaoncologyradiation oncologyleukemiaepcore fl-1versus lenalidomidehematological malignanciesjama oncologyrefractory follicular lymphoma

1
2
3
4
5
15
10 / page

Adam Kittai

Oregon Health & Science University

Affiliations

OHSU School of Medicine

Department Of Medicine

Department of Medicine

Division of Hematology & Medical Oncology

Department Of Medicine

Hematology and Medical Oncology

Oregon Health & Science University

Honors

Create free account to unlock more features

Experiences

Create free account to unlock more features

Education

Create free account to unlock more features

Adam Kittai

Oregon Health & Science University

You can click a keyword to filter the displayed items

Notable Scholarly Works

Notable Federal Grants

Collaborators

pharmacologymedicineoncologyhematological malignanciesleukemiapharmacotherapyanti-cancer agentsimmunotherapyimmunologymatched‐adjusted indirect comparisonhematology

3: Comparing and Contrasting Karyotype Scoring Guidelines for Evaluating Complex Karyotype in Chronic Lymphocytic Leukemia. Genetics in Medicine Open (2025)

pathologyhuman geneticschronic lymphocytic leukemiamedicinemolecular diagnosticscancer researchhematological malignanciescomplex karyotypeleukemiaadult t-cell leukemia-lymphomahematology

557 | Evaluating Uptake of Targeted Agents by Race/Ethnicity in Patients Receiving First‐Line Treatment for Chronic Lymphocytic Leukemia. Hematological Oncology (2025)

medicinelymphoid neoplasiaoncologyhematological malignanciesleukemiapharmacotherapyimmunologyhematologycancer care

A Phase II Multi-Institutional Study Evaluating the Safety and Efficacy of the Combination of Lisocabtagene Maraleucel and Zanubrutinib in Patients With Richter Transformation. Blood (2025)

clinical trialsoutcomes researchapplied pharmacologymedicinelisocabtagene maraleucelpatient safetypharmacotherapydrug safetyrichter transformationclinical researchsurgery

Consolidation (Cons) and Maintenance (Maint) Approaches in Primary Central Nervous System Lymphoma (Pcnsl) After High-Dose Methotrexate Induction in Transplant-Ineligible Patients. Blood (2025)

Cost Impact of Bruton’s Tyrosine Kinase Inhibitor Selection in Medicare Patients With Chronic Lymphocytic Leukemia. Journal of Comparative Effectiveness Research (2025)

pharmacoeconomicshealth policymedicinecost impactmedicare patientsoncologyhematological malignanciesleukemiapharmacotherapytreatment plan evaluationhealth economicshematologycancer carebruton ’

Cytokine Release Syndrome and Neurotoxicity Following Cd19 Car-T in B-Cell Lymphoma. Transplantation and Cellular Therapy (2025)

cytokinesimmunity (medicine)b-cell lymphomacellular therapyimmunologycytokine release syndrome

Effect of Racial Disparities on Cancer Survival in Hematologic Malignancies: A Population-Based Analysis of Seer Data (2009–2019). Preventive Oncology & Epidemiology (2025)

Alma HabibYing HuangElectra D. PaskettSrinivas DevarakondaJames L. FisherAdam S. Kittai

cancer immunotherapypathologylymphoid neoplasiaoncologyradiation oncologyleukemiaepcore fl-1versus lenalidomidehematological malignanciesjama oncologyrefractory follicular lymphoma

1
2
3
4
5
15
10 / page